Vimarsana
Biggest News Aggregation in the World

Page 7 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System - Vimarsana News

Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System

/PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed...

FDA Approves Dupilumab to Treat EoE for Children Under 12 Years - Vimarsana News

FDA Approves Dupilumab to Treat EoE for Children Under 12 Years

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

Source: ajmc.com
FDA clears Dupixent to treat esophageal condition in kids under 12 - Vimarsana News

FDA clears Dupixent to treat esophageal condition in kids under 12

FDA approves Dupixent for pediatric patients with chronic eosinophilic esophagitis, expanding treatment options for children as young as 1 year old.

MDS Research Expands Treatment Options Across Disease Subsets - Vimarsana News

MDS Research Expands Treatment Options Across Disease Subsets

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A) - Vimarsana News

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)

/PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its...